192 related articles for article (PubMed ID: 31082688)
21. Allogeneic haematopoietic cell transplantation for chronic myeloid leukaemia in Switzerland in the face of rapid development of effective drugs.
Heim D; Baldomero H; Medinger M; Masouridi-Levrat S; Schanz U; Nair G; Güngör T; Halter J; Passweg JR; Chalandon Y;
Swiss Med Wkly; 2024 May; 154():3754. PubMed ID: 38749067
[TBL] [Abstract][Full Text] [Related]
22. Prognostic Factors for Outcomes of Allogeneic HSCT for Children and Adolescents/Young Adults With CML in the TKI Era.
Shimada H; Tanizawa A; Kondo T; Nagamura-Inoue T; Yasui M; Tojo A; Muramatsu H; Eto T; Doki N; Tanaka M; Sato M; Noguchi M; Uchida N; Takahashi Y; Sakata N; Ichinohe T; Hashii Y; Kato K; Atsuta Y; Ohashi K;
Transplant Cell Ther; 2022 Jul; 28(7):376-389. PubMed ID: 35447373
[TBL] [Abstract][Full Text] [Related]
23. Paediatric chronic myeloid leukaemia presenting in de novo or secondary blast phase - a comparison of clinical and genetic characteristics.
Sembill S; Göhring G; Schirmer E; Lutterloh F; Suttorp M; Metzler M; Karow A
Br J Haematol; 2021 May; 193(3):613-618. PubMed ID: 33690887
[TBL] [Abstract][Full Text] [Related]
24. Pathogenesis and management of accelerated and blast phases of chronic myeloid leukemia.
Senapati J; Jabbour E; Kantarjian H; Short NJ
Leukemia; 2023 Jan; 37(1):5-17. PubMed ID: 36309558
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and Safety of Imatinib in Paediatric CML - A Single Centre Study.
Smeding C; Szydło A; Pieluszczak K; Grzeszkiewicz K; Pawelec K
In Vivo; 2019; 33(3):869-875. PubMed ID: 31028210
[TBL] [Abstract][Full Text] [Related]
26. Initial treatment for patients with CML.
Goldman JM
Hematology Am Soc Hematol Educ Program; 2009; ():453-60. PubMed ID: 20008231
[TBL] [Abstract][Full Text] [Related]
27. Generic imatinib in the treatment of chronic myeloid leukemia: two years' experience in Latvia.
Lejniece S; Udre I; Rivkina A
Exp Oncol; 2017 Jul; 39(2):151-154. PubMed ID: 29483494
[TBL] [Abstract][Full Text] [Related]
28. Pattern of chronic myeloid leukemia in the imatinib era in a Sub-Saharan African setting.
Faye BF; Dieng N; Seck M; Gadji M; Gueye YB; Sy D; Toure SA; Sall A; Toure AO; Dieye TN; Diop S
Ann Hematol; 2016 Oct; 95(10):1603-10. PubMed ID: 27370991
[TBL] [Abstract][Full Text] [Related]
29. Health-related quality of life during bosutinib (SKI-606) therapy in patients with advanced chronic myeloid leukemia after imatinib failure.
Whiteley J; Reisman A; Shapiro M; Cortes J; Cella D
Curr Med Res Opin; 2016 Aug; 32(8):1325-34. PubMed ID: 27045164
[TBL] [Abstract][Full Text] [Related]
30. Clinical Features and Treatment Outcomes of 51 Patients with Chronic Myeloid Leukemia Treated with a Tyrosine Kinase Inhibitor at a Single Institution from 2002 to 2014.
Kawano N; Yoshida S; Kawano S; Kuriyama T; Yamashita K; Ochiai H; Shimoda K; Ishikawa F; Ueda A; Kikuchi I
J Clin Exp Hematop; 2016; 56(1):34-42. PubMed ID: 27334856
[TBL] [Abstract][Full Text] [Related]
31. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.
DeAngelo DJ; Hochberg EP; Alyea EP; Longtine J; Lee S; Galinsky I; Parekkedon B; Ritz J; Antin JH; Stone RM; Soiffer RJ
Clin Cancer Res; 2004 Aug; 10(15):5065-71. PubMed ID: 15297408
[TBL] [Abstract][Full Text] [Related]
32. Effect of graft sources on allogeneic hematopoietic stem cell transplantation outcome in adults with chronic myeloid leukemia in the era of tyrosine kinase inhibitors: a Japanese Society of Hematopoietic Cell Transplantation retrospective analysis.
Ohashi K; Nagamura-Inoue T; Nagamura F; Tojo A; Miyamura K; Mori T; Kurokawa M; Taniguchi S; Ishikawa J; Morishima Y; Atsuta Y; Sakamaki H
Int J Hematol; 2014 Sep; 100(3):296-306. PubMed ID: 25085253
[TBL] [Abstract][Full Text] [Related]
33. Chronic myeloid leukemia patients in Tunisia: epidemiology and outcome in the imatinib era (a multicentric experience).
Ben Lakhal R; Ghedira H; Bellaaj H; Ben Youssef Y; Menif S; Manai Z; Bedoui M; Lakhal A; M'Sadek F; Elloumi M; Khélif A; Ben Romdhane N; Laatiri MA; Ben Othmen T; Meddeb B
Ann Hematol; 2018 Apr; 97(4):597-604. PubMed ID: 29305630
[TBL] [Abstract][Full Text] [Related]
34. Ponatinib in childhood Philadelphia chromosome-positive leukaemias: an international registry of childhood chronic myeloid leukaemia study.
Millot F; Suttorp M; Versluys AB; Kalwak K; Nelken B; Ducassou S; Bertrand Y; Baruchel A
Eur J Cancer; 2020 Sep; 136():107-112. PubMed ID: 32668374
[TBL] [Abstract][Full Text] [Related]
35. Does Post-Transplant Maintenance Therapy With Tyrosine Kinase Inhibitors Improve Outcomes of Patients With High-Risk Philadelphia Chromosome-Positive Leukemia?
DeFilipp Z; Langston AA; Chen Z; Zhang C; Arellano ML; El Rassi F; Flowers CR; Kota VK; Al-Kadhimi Z; Veldman R; Jillella AP; Lonial S; Waller EK; Khoury HJ
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16(8):466-471.e1. PubMed ID: 27297665
[TBL] [Abstract][Full Text] [Related]
36. Allogeneic Stem Cell Transplantation for Patients with T315I BCR-ABL Mutated Chronic Myeloid Leukemia.
Xu LP; Xu ZL; Zhang XH; Chen H; Chen YH; Han W; Chen Y; Wang FR; Wang JZ; Wang Y; Yan CH; Mo XD; Liu KY; Huang XJ
Biol Blood Marrow Transplant; 2016 Jun; 22(6):1080-1086. PubMed ID: 26995693
[TBL] [Abstract][Full Text] [Related]
37. When to Consider Allogeneic Transplantation in CML.
Radich J
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S93-5. PubMed ID: 27521333
[TBL] [Abstract][Full Text] [Related]
38. Chronic myeloid leukemia (CML) in children and adolescents-Clinicopathological findings.
Nevejan L; Labarque V; Boeckx N
Eur J Haematol; 2024 Mar; 112(3):458-465. PubMed ID: 37985225
[TBL] [Abstract][Full Text] [Related]
39. Dasatinib treatment for imatinib resistant or intolerant patients with chronic myeloid leukaemia.
Li J; Xu G; Yu S; He L; Guo L
J Int Med Res; 2011; 39(2):337-47. PubMed ID: 21672337
[TBL] [Abstract][Full Text] [Related]
40. Allogeneic blood stem cell transplantation in chronic myeloid leukaemia-chronic phase following conditioning with busulphan and cyclophosphamide: a follow up report.
Saikia TK; Parikh PM; Tawde S; Amare-Kadam PS; Rajadhyaksha S; Chhaya S
Natl Med J India; 2004; 17(2):71-3. PubMed ID: 15141598
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]